Cantor Fitzgerald Reiterates Overweight Rating on Avita Medical Ltd. (RCEL)

Cantor Fitzgerald analyst Ross Osborne reiterated an Overweight rating and $11.00 price target on Avita Medical Ltd. (NASDAQ: RCEL).

The analyst commented, "On 9/15, AVITA Medical (RCEL, OW) announced CE Mark approval for RECELL GO, the company's next-generation autologous cell harvesting device. Recall that RECELL GO improves on the legacy RECELL offering by eliminating the need for manual management of skin samples, thereby reducing the training burden on medical staff. Additionally, RCEL expects to initiate commercialization of RECELL GO in Germany, Italy and the United Kingdom in collaboration with leading burn centers and clinical partners."

For an analyst ratings summary and ratings history on Avita Medical Ltd. click here. For more ratings news on Avita Medical Ltd. click here.

Shares of Avita Medical Ltd. closed at $5.47 yesterday.

You May Also Be Interested In

• Bessent: U.S. will enforce 'zero leakage' approach to Iran sanctions
• U.S. Treasury sanctions nearly 60 Iran-linked entities, people and vessels across nuclear, missile, cyber and oil networks
• US Eyes 7.5% China Overcapacity Tariffs Before Xi-Trump Talks - Bloomberg